📢 Moving away from chemotherapy in Ph-positive #ALL out in BJH @kouriehr @MDAndersonNews ➡️  https://t.co/vtVKXTSMKV

«Longer overall survival with CAR-T cells than standard care» just published in the ⁦@NEJM⁩ Advances in hematology have been impressive in the last 10 years! And more is yet to come! ⁦@TheIACH⁩ is committed to high level education and to disseminate all these advances

#MRF #MikaelRayaanFoundation

Summary on the management of Ph-like #ALL ➡️ TKIs effective in patients with ABL1 or ABL2 fusions, mostly in the first-line setting ➡️ ANTIBODIES (InO, blina) improve outcomes ➡️ Favor transplant in CR1 #leusm @NitinJainMD @jayastuMD @_MDEducation

#CARTsm #ALLsm Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR (r/r B-ALL): Results of the FELIX study. https://t.co/p39ikuRcep Would you consider over brexu-cel? If so, why? @hemedoc @NitinJainMD @DrHKantarjian @NicholasShortMD

Honored to photograph the legend @carlhjune #celebrityphotography #bucketlistitem #CART #immunology

Most aesthetic venue for a conference #CelliconValley #penn ✨✨

#CelliconValley Impressive trends and long term outcomes of #CART at #CHOP #ALL @GruppSteve

#CART Curative Potential for ALL: To transplant or not? Role of MRD. @GruppSteve #CelliconValley

Long term CAR T data in lymphoma "Likelihood of being alive at 5 years after infusion is 91% (without an EFS event by 12 mo)" @fredlock #CelliconValley

#CelliconValley Long Term Data in Lymphoma @DrFredLocke @GruppSteve #penn

#CelliconValley Global expansion of #CART cell therapy: insights from Puerto Rico, Australia, Saudi Arabia and India. Great start, long way to go… @shahrukhhashmi #immuneel #penn

#CelliconValley CAR T Response Prediction and Mechanisms of Resistance #Standford #penn #CARTsm @DavidBMiklos

This. #CARTsm #CRS #ICANS #CelliconValley

#CARTsm CAR T complications: Anakinra and other interventions: #CelliconValley #penn

#CelliconValley CAR T complications/prophylaxis: ZUMA 1 cohorts 3, 4, 6, and lessons. #penncancer @CARTTherapy

#CARTsm #Celliconvalley Toxicity and Toxicity Management (CRS prophylaxis and ICANS) #NoelleFrey 2/2

#CARTsm #Celliconvalley Toxicity and Toxicity Management (CRS prophylaxis and ICANS) #NoelleFrey ICANS > toci ineffective, may worsen 1/2

Oral: Dysfunctional T-Cells in Leukapheresis Associated with Lack of Response to CAR T cells in R/R B-cell NHL #CelliconValley @penn 2/2

Oral: Dysfunctional T-Cells in Leukapheresis Associated with Lack of Response to CAR T cells in R/R B-cell NHL #CelliconValley @penn 1/2